SCH-1473759 hydrochloride

• CAT Number: I000397
• CAS Number: 1094067-13-6
• Molecular Formula: C20H27ClN8OS
• Molecular Weight: 463.00
• Purity: ≥95%
• Target: Aurora Kinase
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• IC50: 4 nM (Aurora A); 13 nM (Aurora B)[1].
• IUPAC Name: 2-[ethyl-[[5-[[6-methyl-3-(1H-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]amino]-1,2-thiazol-3-yl]methyl]amino]-2-methylpropan-1-ol;hydrochloride
• InChI: InChI=1S/C20H26N8OS.ClH/c1-5-27(20(3,4)12-29)11-15-6-17(30-26-15)25-18-19-21-9-16(14-7-22-23-8-14)28(19)10-13(2)24-18;/h6-10,29H,5,11-12H2,1-4H3,(H,22,23)(H,24,25);1H
• InChIKey: YBAZMWNWFHDNTH-UHFFFAOYSA-N
• SMILES: CCN(CC1=NSC(=C1)NC2=NC(=CN3C2=NC=C3C4=CNN=C4)C)C(C)(C)CO.Cl

SCH-1473759 hydrochloride（Cat No.:I000397）is a selective inhibitor of the protein kinase TGF-β-activated kinase 1 (TAK1), which plays a crucial role in regulating inflammatory and stress response signaling pathways. By inhibiting TAK1, SCH-1473759 modulates various cellular processes, including apoptosis, inflammation, and cellular proliferation. This compound has shown potential in preclinical studies for treating conditions associated with chronic inflammation, autoimmune diseases, and cancer. Ongoing research focuses on its pharmacological profile, efficacy, and safety in clinical settings, aiming to position SCH-1473759 as a promising therapeutic candidate in targeted therapies for various diseases.

Reference

[1]. Yu T, et al. Discovery of a Potent, Injectable Inhibitor of Aurora Kinases Based on the Imidazo-[1,2-a]-Pyrazine Core. ACS Med Chem Lett. 2010 Jun 7;1(5):214-8.
[2]. Basso AD, et al. SCH 1473759, a novel Aurora inhibitor, demonstrates enhanced anti-tumor activity in combination with taxanes and KSP inhibitors. Cancer Chemother Pharmacol. 2011 Oct;68(4):923-33.